These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17458164)

  • 1. Intranasal antisense therapy: preclinical models with a clinical future?
    Bitko V; Barik S
    Curr Opin Mol Ther; 2007 Apr; 9(2):119-25. PubMed ID: 17458164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense and RNAi: powerful tools in drug target discovery and validation.
    Lavery KS; King TH
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):561-9. PubMed ID: 12951819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense oligonucleotide therapy in urology.
    Kausch I; Böhle A
    J Urol; 2002 Jul; 168(1):239-47. PubMed ID: 12050550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense applications for biological control.
    Pan WH; Clawson GA
    J Cell Biochem; 2006 May; 98(1):14-35. PubMed ID: 16440307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral delivery of siRNA and antisense oligonucleotides.
    Akhtar S
    J Drug Target; 2009 Aug; 17(7):491-5. PubMed ID: 19530907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers.
    Fattal E; Bochot A
    Int J Pharm; 2008 Dec; 364(2):237-48. PubMed ID: 18619528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligonucleotide technology: from EST to therapeutics.
    Giles RV
    Curr Opin Mol Ther; 2000 Jun; 2(3):238-52. PubMed ID: 11249617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled delivery of antisense oligonucleotides: a brief review of current strategies.
    Zhao X; Pan F; Holt CM; Lewis AL; Lu JR
    Expert Opin Drug Deliv; 2009 Jul; 6(7):673-86. PubMed ID: 19552611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. siRNA delivery systems for cancer treatment.
    Oh YK; Park TG
    Adv Drug Deliv Rev; 2009 Aug; 61(10):850-62. PubMed ID: 19422869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers.
    Amantana A; Iversen PL
    Curr Opin Pharmacol; 2005 Oct; 5(5):550-5. PubMed ID: 16087398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides.
    White PJ; Anastasopoulos F; Pouton CW; Boyd BJ
    Expert Rev Mol Med; 2009 Mar; 11():e10. PubMed ID: 19302730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense oligodeoxynucleotide therapy for bladder cancer: recent advances and future prospects.
    Miyake H; Hara I; Fujisaw M; Gleave ME
    Expert Rev Anticancer Ther; 2005 Dec; 5(6):1001-9. PubMed ID: 16336091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense strategies in degenerative joint diseases: sense or nonsense?
    Huber LC; Distler O; Gay RE; Gay S
    Adv Drug Deliv Rev; 2006 May; 58(2):285-99. PubMed ID: 16574269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral delivery of small RNA and DNA.
    Forbes DC; Peppas NA
    J Control Release; 2012 Sep; 162(2):438-45. PubMed ID: 22771979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspects of the transport and delivery of antisense oligonucleotides.
    Juliano RL; Yoo H
    Curr Opin Mol Ther; 2000 Jun; 2(3):297-303. PubMed ID: 11249624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense inhibitors, ribozymes, and siRNAs.
    Thompson AJ; Patel K
    Clin Liver Dis; 2009 Aug; 13(3):375-90. PubMed ID: 19628155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymer nanocarriers for the delivery of small fragments of nucleic acids: oligonucleotides and siRNA.
    de Martimprey H; Vauthier C; Malvy C; Couvreur P
    Eur J Pharm Biopharm; 2009 Mar; 71(3):490-504. PubMed ID: 18977435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of microRNA with antisense oligonucleotides.
    Esau CC
    Methods; 2008 Jan; 44(1):55-60. PubMed ID: 18158133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Current status of antisense drugs].
    Li XJ
    Sheng Li Ke Xue Jin Zhan; 2000 Apr; 31(2):115-9. PubMed ID: 12545727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nasal delivery of siRNA.
    Bitko V; Barik S
    Methods Mol Biol; 2008; 442():75-82. PubMed ID: 18369779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.